Global Soliris Market Outlook 2022

Eculizumab, sold under the trade name Soliris, is a medication used to treat paroxysmal nocturnal hemoglobinuria (PHN) and atypical hemolytic uremic syndrome (aHUS). It is a humanized monoclonal antibody functioning as a terminal complement inhibitor. In people with PNH, it reduces both the destruction of red blood cells and need for blood transfusion, but does not appear to affect the risk of death. Eculizumab was the first drug approved for each of its uses, and its approval was granted on the basis of small clinical trials.
Prior to COVID-19, the China market for Soliris was anticipated to grow from US$ 43.15 million in 2020 to US$ 105.67 million by 2026; it is expected to grow at a CAGR of 14.86% during 2021–2026, whereas post-COVID-19 scenario, the market for Soliris is projected to grow from US$ 40.9 million in 2020 (a change by ~-6.4% compared to market estimated for 2020 before the outbreak of COVID-19) to US$ 100.58 million by 2026; it is expected to grow at a CAGR of 14.75% during 2021–2026. The solicitation of proposals by the governments and public–private companies across the world to mitigate the impact of the COVID-19 pandemic is the key factor propelling the growth of the Soliris market.The classification of Soliris includes Plasma Exchange and Plasma Infusion, and the proportion of Plasma Exchange in 2019 is about 76.36%, and the proportion is in increasing trend from 2013 to 2018.

Soliris is widely used for patients of PNH, aHUS and other. The most proportion of Soliris is used for patients of PNH, and the proportion in 2019 is 66.85%.

The global Soliris market was valued at US$ million in 2020 and is expected to reach US$ million by the end of 2027, growing at a CAGR of % during 2021-2027.
This report focuses on Soliris volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Soliris market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.

Global Soliris Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type
Plasma Exchange
Plasma Infusion

Segment by Application
PNH
aHUS
Other

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

By Company
Alexion